Clinical Trial Update: Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of bortezomib, liposomal doxorubicin, and dexamethasone for plasma cell leukemia, with multiple myeloma listed as related…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Clinical Service, China | Conditions: Plasma Cell Leukemia, Multiple Myeloma | Phase 2 | Status: UNKNOWN